Loading…
CIK 0001560009 • 6 13F filings • May 7, 2025 – Aug 12, 2026
Import this data to Google Sheets with:
=jivedata("versant-venture-management-llc","13f")Uses this filer's slug. Install the Jive Data add-on first; the second argument is "13f".
Past 5 quarters
| % of Portfolio | |||||
|---|---|---|---|---|---|
| Contineum Therapeutics, Inc. | Common Stock | $6.2M | 4.1%Prev: 3.0% | 542,628 SH | Decreased |
| CRISPR Therapeutics AG | Common Shares | $7.8M | 5.2%Prev: 4.5% | 148,831 SH | Decreased |
| Jade Biosciences, Inc. | Common Stock | $23.5M | 15.6%Prev: 6.2% | 1,525,820 SH | Increased |
| Lenz Therapeutics, Inc. | Common Stock | $42.5M | 28.1%Prev: 58.3% | 2,656,888 SH | Decreased |
| Monte Rosa Therapeutics, Inc. | Common Stock | $68.7M | 45.5%Prev: 19.7% | 4,382,687 SH | Increased-1,270,235 SH |
| Skye Bioscience, Inc. | Common Stock | $1.5M | 1.0%Prev: 3.7% | 2,007,704 SH | Decreased |
| Tempest Therapeutics, Inc. | Common Stock | $774K | 0.5%Prev: 1.3% | 269,772 SH | Decreased |
| 13F-HR |
| 0001193125-26-347068 |
| $162.6M |
| View |
| Aug 11, 2025 | Q2 2025 | 13F-HR | 0000950123-25-007471 | $82.1M | View |
| May 5, 2026 | Q1 2026 | 13F-HR | 0001193125-26-206555 | $141.4M | View |
| May 7, 2025 | Q1 2025 | 13F-HR | 0000950123-25-004223 | $60.2M | View |